New rules in Canada to address Rx drug abuse

21 November 2012

To launch National Addictions Awareness Week, Canada’s Federal Minister of Health Leona Aglukkaq, and Shelly Glover, Parliamentary Secretary to the Minister of Finance, announced tough new licensing rules that aim to clamp down on the diversion of controlled release formulations of oxycodone products - prescription drugs that are at a high risk of abuse.

In a letter to her provincial and territorial counterparts, Ms Aglukkaq called on provincial and territorial governments, as well as medical professionals, to look at what they can do within their areas of jurisdiction to tackle the serious problem of prescription drug abuse.

"Our government is taking action to tackle prescription drug abuse," said Ms Aglukkaq, adding: "This is a serious issue that destroys the lives of individuals and families, and I believe we have the responsibility to work with the provinces and territories to address it head-on."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical